Literature DB >> 23365461

Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.

Der-Cherng Liang1, Hsi-Che Liu, Chao-Ping Yang, Tang-Her Jaing, Iou-Jih Hung, Ting-Chi Yeh, Shih-Hsiang Chen, Jen-Yin Hou, Ying-Jung Huang, Yu-Shu Shih, Yu-Hui Huang, Tung-Huei Lin, Lee-Yung Shih.   

Abstract

Gene mutations involving epigenetic regulators recently have been described in adult acute myeloid leukemia (AML). Similar studies are limited in children. We analyzed gene mutations and cooperation in pediatric AML with special reference on mutated epigenetic regulators. Nineteen gene mutations, including 8 class I genes, 4 class II genes, WT1 and TP53 (class III), and 5 epigenetic regulator genes (class IV), were analyzed in 206 children with de novo AML. Mutational analysis was performed with polymerase chain reaction-based assay followed by direct sequencing. One hundred seventeen of 206 patients (56.8%) had at least one mutation: 51% class I, 13% class II, 6.8% class III, and 5.6% class IV. FLT3-internal tandem duplication was most frequent, and 29% of patients had more than one gene mutation. Two patients carried ASXL1 mutations, both with t(8;21), 2 had DNMT3A mutations, 2 had IDH1 mutations, 1 had IDH2 mutation, and 3 had TET2 mutations. Both patients with IDH1 mutations had AML-M0 subtype and MLL-partial tandem duplication. Cooperating mutations with mutated epigenetic regulators were observed in 8 of 10 patients. We conclude that mutated epigenetic regulators were much less than those in adult AML but with frequent cooperating mutations. ASXL1, TET2, and IDH1 mutations were associated with specific genetic subtypes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365461     DOI: 10.1182/blood-2012-06-436782

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  38 in total

1.  Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia.

Authors:  Yukiko Yano; Courtney Schiffman; Hasmik Grigoryan; Josie Hayes; William Edmands; Lauren Petrick; Todd Whitehead; Catherine Metayer; Sandrine Dudoit; Stephen Rappaport
Journal:  Leuk Res       Date:  2019-11-06       Impact factor: 3.156

2.  PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.

Authors:  Chengli Song; Lina Wang; Xiaoyan Wu; Kai Wang; Dan Xie; Qi Xiao; Songyu Li; Kui Jiang; Lujian Liao; John R Yates; Jiing-Dwan Lee; Qingkai Yang
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

Review 3.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 4.  The de novo DNA methyltransferase DNMT3A in development and cancer.

Authors:  Bi-Feng Chen; Wai-Yee Chan
Journal:  Epigenetics       Date:  2014-03-03       Impact factor: 4.528

5.  Mapping epigenetic regulator gene mutations in cytogenetically normal pediatric acute myeloid leukemia.

Authors:  Daria G Valerio; Jenny E Katsman-Kuipers; Joop H Jansen; Lonneke J Verboon; Valerie de Haas; Jan Stary; André Baruchel; Martin Zimmermann; Rob Pieters; Dirk Reinhardt; Marry M van den Heuvel-Eibrink; C Michel Zwaan
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 6.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

Review 7.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

8.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

Review 9.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

Review 10.  Cytosine modifications in neurodevelopment and diseases.

Authors:  Bing Yao; Peng Jin
Journal:  Cell Mol Life Sci       Date:  2013-08-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.